pubmed-article:1974144 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1974144 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
pubmed-article:1974144 | lifeskim:mentions | umls-concept:C0553982 | lld:lifeskim |
pubmed-article:1974144 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:1974144 | lifeskim:mentions | umls-concept:C0475224 | lld:lifeskim |
pubmed-article:1974144 | lifeskim:mentions | umls-concept:C0165214 | lld:lifeskim |
pubmed-article:1974144 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:1974144 | pubmed:dateCreated | 1990-9-13 | lld:pubmed |
pubmed-article:1974144 | pubmed:abstractText | 1. The haemodynamic effects of a new cardioselective postsynaptic alpha 1-adrenoceptor antagonist UK-52,046, were evaluated in 25 patients with stable coronary disease, with or without impaired left ventricular function. At rest the haemodynamic effects to two dose-response regimens were determined. In an initial eight patients 0.125, 0.125 and 0.25 micrograms kg-1 were administered peripherally at 15 min intervals; the haemodynamic measurements were determined between 10 to 15 min after each dose. In a further 17 patients, the dose regimen was doubled yielding a cumulative dose-regimen of 0.25, 0.5 and 1.0 micrograms kg-1. The exercise effects were determined by comparison of measurements during 4 min of supine sub-maximal bicycle exercise at a fixed workload before and after drug treatment. 2. At rest, the lower dose regimen of UK-52,046 significantly reduced systemic mean arterial blood pressure (-5 mm Hg; P less than 0.05) and increased cardiac index (+0.2 l min-1 m-2, P less than 0.01). The higher dose regimen of UK-52,046 reduced systemic mean arterial blood pressure (-7 mm Hg; P less than 0.01), pulmonary artery occluded pressure (PAOP) (-2 mm Hg, P less than 0.01) and vascular resistance index (-314 dyn s cm-5 m2; P less than 0.05) with an increase in heart rate (+7%, P less than 0.05) and cardiac index (+0.2 l min-1 m-2, P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:language | eng | lld:pubmed |
pubmed-article:1974144 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:1974144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1974144 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1974144 | pubmed:month | Jun | lld:pubmed |
pubmed-article:1974144 | pubmed:issn | 0306-5251 | lld:pubmed |
pubmed-article:1974144 | pubmed:author | pubmed-author:TaylorS HSH | lld:pubmed |
pubmed-article:1974144 | pubmed:author | pubmed-author:VermaS PSP | lld:pubmed |
pubmed-article:1974144 | pubmed:author | pubmed-author:SilkeBB | lld:pubmed |
pubmed-article:1974144 | pubmed:author | pubmed-author:ThamT CTC | lld:pubmed |
pubmed-article:1974144 | pubmed:author | pubmed-author:ZezulkaA VAV | lld:pubmed |
pubmed-article:1974144 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1974144 | pubmed:volume | 29 | lld:pubmed |
pubmed-article:1974144 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1974144 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1974144 | pubmed:pagination | 749-58 | lld:pubmed |
pubmed-article:1974144 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:meshHeading | pubmed-meshheading:1974144-... | lld:pubmed |
pubmed-article:1974144 | pubmed:year | 1990 | lld:pubmed |
pubmed-article:1974144 | pubmed:articleTitle | Haemodynamic dose-response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular function. | lld:pubmed |
pubmed-article:1974144 | pubmed:affiliation | University Department of Cardiovascular Studies, General Infirmary, Leeds. | lld:pubmed |
pubmed-article:1974144 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1974144 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1974144 | lld:pubmed |